Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Shares Issued (2020 - 2024)

Historic Shares Issued for SAB Biotherapeutics (SABS) over the last 5 years, with Q4 2024 value amounting to -$3.0.

  • SAB Biotherapeutics' Shares Issued fell 10000.0% to -$3.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $20409.0, marking a year-over-year decrease of 9996.58%. This contributed to the annual value of $20409.0 for FY2024, which is 9996.58% down from last year.
  • As of Q4 2024, SAB Biotherapeutics' Shares Issued stood at -$3.0, which was down 10000.0% from $20412.0 recorded in Q1 2024.
  • SAB Biotherapeutics' 5-year Shares Issued high stood at $59.6 million for Q4 2023, and its period low was -$4.2 million during Q4 2021.
  • Its 5-year average for Shares Issued is $5.6 million, with a median of $14121.0 in 2022.
  • As far as peak fluctuations go, SAB Biotherapeutics' Shares Issued crashed by 1676100.0% in 2021, and later soared by 24290000.0% in 2023.
  • SAB Biotherapeutics' Shares Issued (Quarter) stood at $25000.0 in 2020, then tumbled by 16761.0% to -$4.2 million in 2021, then surged by 282.55% to $7.6 million in 2022, then surged by 684.47% to $59.6 million in 2023, then crashed by 100.0% to -$3.0 in 2024.
  • Its last three reported values are -$3.0 in Q4 2024, $20412.0 for Q1 2024, and $59.6 million during Q4 2023.